X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

SELB

Closed

Selecta Biosciences Inc

0.7465
+0.0322 (+4.51%)
Last Update: 26 Dec 2023 17:30:00
Yesterday: 0.7143
Day's Range: 0.71 - 0.7879
Send
When Written:
 
1.29
Selecta Biosciences Inc. is a clinical-stage biotechnology company that develops targeted immunotherapies for rare and serious diseases. The company's proprietary Synthetic Vaccine Particle (SVP) technology is designed to induce antigen-specific immune responses to potentially treat and prevent diseases such as cancer, autoimmune disorders, and infectious diseases. Selecta's lead product candidate, SEL-212, is being developed for the treatment of chronic refractory gout, a debilitating and painful disease caused by the buildup of uric acid crystals in the joints. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X